Patients with the luminal B subtype of breast cancer exhibit a poor prognosis, high metastatic risk and high incidence of chemotherapy resistance. Luminal B breast cancer is sub-classified into B1 and B2. The pathophysiological mechanism of luminal B2 breast cancer (LB2BC) progression has yet to be characterized. Therefore, the present study aimed to identify the genes involved in the pathogenesis of LB2BC. The data of 117 LB2BC expression profiles were downloaded from The Cancer Genome Atlas (TCGA) and differentially expressed genes (DEGs) were identified by comparison with non-tumor tissue expression profiles. Gene Ontology enrichment analysis, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis and protein-protein interaction (PPI) networks were used to obtain insight into the functions of DEGs. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis was performed to validate the expression level of DEGs in tissue samples. A total of 2,251 DEGs, including 759 upregulated and 1,492 downregulated genes, were identified between LB2BC and non-tumor tissues. The top 15 upregulated and downregulated genes were used to construct a PPI network: Epidermal growth factor receptor (EGFR), fibronectin-1 (FN1) and Polo-like kinase-1 had the highest connectivity degrees. KEGG analysis identified that DEGs were most significantly enriched in 'focal adhesion', 'pathways in cancer' and 'ECM-receptor interaction' pathways. The results of RT-qPCR demonstrated that EGFR was significantly downregulated in LB2BC, whereas FN1 was significantly upregulated, whereas neurotrophic receptor tyrosine kinase 2 (NTRK2) trended towards downregulation. In conclusion, the DEGs identified in the present study, including NTRK2, FN1 and EGFR, may serve pivotal roles in the tumorigenesis of LB2BC by affecting the 'focal adhesion', 'pathways in cancer' and 'ECM-receptor interaction' KEGG pathways.
Introduction
Breast cancer, a complex and heterogeneous malignancy, is the most frequently diagnosed cancer and the leading cause of cancer mortality among females worldwide; there were estimated to be 1.7 million cases and 521,900 deaths in 2012 (1). The incidence rates of breast cancer in economically developed regions, including North America, Australia, New Zealand, and Northern and Western Europe, are higher than those in Africa and Asia (1) .
Breast cancer is classified into 4 subtypes: Luminal A, luminal B, human epidermal growth factor receptor 2 (HER2) -positive and basal-like, according to clinically and biologically relevant molecular features that were previously identified by DNA microarray-based expression profiling (2) (3) (4) . These subtypes are associated with distinct pathological features, treatment responses and clinical outcomes (5) . Basal-like breast cancer is predominantly triple-negative (i.e. no expression of estrogen receptor (ER), progesterone receptor (PR) or HER2). In HER2-positive breast cancer, the HER2 gene is overexpressed. The basal-like and HER2-positive subtypes are associated with a poor prognosis, and the luminal A subtype was identified as having the more favorable clinical outcome (4) .
The clinical and biological behavior of the luminal B subtype is more aggressive than the luminal A subtype, with a higher metastatic risk and greater resistance to hormone therapy and conventional chemotherapy; patients with luminal B cancer exhibit increased relapse rates in the first 5 years following diagnosis (6) . Luminal B-subtype cancer cases have a higher recurrence score than luminal A, based on OncotypeDX detection: In a cohort of 831 untreated lymph node metastasis-negative patients, the hazard ratio (HR) for early metastasis (<5 years) was 2.86 for luminal B relative to luminal A (6, 7) .
As a subtype of Luminal B breast cancer, luminal B2 breast cancer (LB2BC) is usually associated with poor prognosis, and the pathophysiological mechanism underlying luminal B2 breast cancer remains unknown. In the present study, Bioinformatics analysis of gene expression profiles to identify causal genes in luminal B2 breast cancer bioinformatics methods were used to identify differentially expressed genes (DEGs) between LB2BC and non-tumor tissues, with the aim of providing valuable information for further pathogenesis mechanism elucidation of LB2BC.
Subjects and methods
TGCA data. All 1,098 patients (as included in the database on the 27th of October, 2015) with breast cancer were retrieved from The Cancer Genome Atlas (TGCA) data portal (8) . A total of 117 LB2BC expression profiles from this dataset were included in the present study, according to the inclusion and exclusion criteria below. Level 3 raw expression data of mRNA from the Illumina HiSeq_miRNAseq V2 platform for the 117 LB2BC profiles and 18 normal controls were downloaded from TCGA data portal.
Exclusion criteria. The exclusion criteria for patients with LB2BC were as follows: i) History of any other malignancy; ii) history of previous treatment, including chemotherapy, radiotherapy or endocrinotherapy; iii) samples without mRNA sequence data.
Inclusion criteria. The inclusion criteria were as follows: i) HER2 status, as assessed by immunohistochemistry (IHC), was positive; ii) ER expression, PR expression, or both, were positive.
Screening of differentially expressed genes. In R (version 3.2.3), the DESeq (version 1.28.0) package was used for reads count analysis (9) . The limma package (version 1.9.6) (10) was used to screen for DEGs by comparing LB2BC expression profiles to control profiles. The raw P-value was adjusted to a false discovery rate (FDR) value using the Benjamin and Hochberg method. Genes within the cut-off criteria of FDR<0.001 were designated as DEGs.
Functional annotation of DEGs. To identify the biological function and associated metabolic pathways for the DEGs, they were submitted to the Kyoto Encyclopedia of Genes and Genomes (KEGG) database for pathway enrichment analysis and GOrilla online software (11) for gene ontology (GO) term enrichment analysis (12, 13) . P<0.001 and FDR<0.05 were set as the cut-offs for selecting significantly enriched functional GO terms and KEGG pathway, respectively.
Construction of protein-protein interaction (PPI) network.
A PPI network can organize genes into a network to aid the understanding of their biological function (13) . The BioGRID database (14) includes verified and predicted protein interactions. In the present study, DEGs were mapped into the BioGRID database to screen for interacting protein pairs (15 (17), normalized to β-actin. Each reaction was performed ≥3 times.
The primer sequences were as follows: Neurotrophic receptor tyrosine kinase 2 (NTRK2) forward, 5'-ATC TCC AAC CTC AGA CCA CCACT-3' and reverse, 5'-AAT CTG TTT CTC ATC CTT CCC ATAC-3'; fibronectin-1 (FN1) forward, 5'-CAA CCT ACG GAT GAC TCG TGCTT-3' and reverse, 5'-TTT CTC CCT GAC GGT CCC ACTT-3'; Polo-like kinase 1 (PLK1) forward, 5'-GGC AGC GTG CAG ATC AACTT-3' and reverse, 5'-CAG GAG ACT CAG GCG GTA TGT-3'; epidermal growth factor receptor (EGFR) forward, 5'-GTG ACC GTT TGG GAG TTG ATGA-3' and reverse, 5'-GGC TGA GGG AGG CGT TCTC-3'); and β-actin forward, 5'-CTG AAG TAC CCC ATC GAG CAC-3' and reverse, 5'-ATA GCA CAG CCT GGA TAG CAAC-3' .
Statistical analysis. RT-qPCR experimental data were expressed as the mean ± standard deviation. GraphPad Prism (version 6.0) software (GraphPad Software, Inc., La Jolla, CA, USA) was used to perform statistical analysis. Statistically significant differences between two groups were evaluated using an unpaired Student's t-test. P<0.05 was considered to indicate a statistically significant difference.
Results

DEGs in LB2BC.
A total of 2,251 significantly DEGs were identified in LB2BC tissues compared with non-tumor controls. The DEGs included 759 upregulated and 1,492 downregulated genes. Matrix metalloproteinase-11 was the most significantly upregulated gene; NTRK2 was the most significantly downregulated gene. The top 15 significantly upregulated and downregulated genes are listed in Table I . The pattern of expression change for the top 200 DEGs is presented in Fig. 1 .
GO annotation of DEGs.
To obtain insights into their potential biological roles, GO term enrichment analysis was performed on the DEGs from LB2BC. 'Mitotic cell cycle process' (GO, 1903047; P=1.22x10 -8 ), 'cell cycle G2/M phase transition' (GO, 0044839; P=7.43x10 -7 ) and 'G2/M transition of mitotic cell cycle' (GO, 0000086; P=7.43x10 -7 ) were the most significantly enriched biological process GO terms; 'vinculin binding' (GO, 0017166; P=5.02x10 -6 ), 'structural constituent of muscle' (GO, 0008307; P=1.53x10 -5 ) and 'potassium channel regulator activity' (GO, 0015459; P=2.77x10 -5 ) were the most significantly enriched molecular function GO terms; 'condensed chromosome outer kinetochore' (GO, 0000940; P=2.34x10 -5 ), 'extracellular matrix' (GO, 0031012; P=4.08x10 -5 ) and 'microtubule spindle' (GO, 0005876; P=8.77x10 -5 ) were the most significantly enriched cellular component GO terms (Table II) .
Pathway enrichment analysis. KEGG pathway enrichment analysis was performed on the DEGs from LB2BC. FDR<0.05 was used as the cut-off for pathway significance.
The most significantly enriched pathways were 'focal adhesion' (FDR=1.02x10 -20 ), 'pathways in cancer' (FDR=1.50x10 -20 ), 'ECM-receptor interactions' (FDR=1.15x10 -14 ) and 'cytokine-cytokine receptor interaction' (FDR=1.50x10 -11 ; Table III ).
Protein-protein interaction (PPI) network construction.
PPI networks for the top 15 upregulated and downregulated DEGs were constructed using Cytoscape software. The network consisted of 1,681 nodes and 1,898 edges. The hub proteins were EGFR, FN1 and PLK1 (Fig. 2) .
RT-qPCR verification of DEGs.
The expression level of four of the identified DEGs (NTRK2, FN1, PLK1 and EGFR) were validated with RT-qPCR in five LB2BC tumor and adjacent tissue samples. The expression of NTRK2 did not differ significantly between LB2BC tumor and adjacent tissues, but trended towards downregulation in LB2BC (Fig. 3A) . The expression of FN1 was significantly upregulated in LB2BC (P<0.05; Fig. 3B ). PLK1 expression did not differ significantly between LB2BC and adjacent tumor tissues (Fig. 3C) . The expression of EGFR was significantly downregulated in LB2BC compared with adjacent tissue (P<0.001 Fig. 3D ).
Discussion
NTRK2 was the most significantly downregulated DEG identified in LB2BC (Table I ) and was associated with the KEGG term 'MAPK signaling pathway' (Table III) . The expression of NTRK2 did not significantly differ between LB2BC and non-cancerous tissue, although it trended towards downregulation in LB2BC (Fig. 3A) . NTRK2 is a member of the neurotrophic tyrosine receptor kinase family. The expression of NTRK2 was previously identified through microarray analysis to be downregulated in patients with breast cancer with a relatively poor prognosis (18) . NTRK2 expression leads to anoikis resistance in several types of cancer, including ovarian cancer (19, 20) . NTRK2 is a direct target of microRNA (miR)-200c; miR-200c decreases the endogenous expression of NTRK2 and mediated the suppression of anoikis resistance in breast cancer cells (21) . In the present study, FN1 was identified as a top-10 upregulated DEG in LB2BC (Table I) . RT-qPCR analysis identified that FN1 was significantly upregulated in LB2BC (Fig. 3B ), in accord with the DEG analysis. FN1 was one of the hub proteins in the PPI network (Fig. 2) . FN1 is a glycoprotein present in a soluble dimeric form in plasma, and in a dimeric or multimeric form at the cell surface and the extracellular matrix (22) . FN1 is associated with cell adhesion, cell migration, wound healing and cell metastasis (23) . FN1 is upregulated in breast cancer; FN1 was also identified as hub protein in a previously constructed PPI network (24) . Previous gene regulatory network analysis of breast cancer demonstrated that FN1 was upregulated in aggressive breast cancer cell lines and was associated with the aggressive behavior of breast cancer cells (25) . The expression of FN1 is a positive predictor for breast cancer cell line sensitivity to paclitaxel (26) . The elevated expression of FN1 promotes vascular endothelial growth factor-C expression and the epithelial-mesenchymal transition, promoting lymph node metastasis in human oral squamous cell carcinoma (27) . FN1 was associated with 5 significantly enriched KEGG pathways, including 'focal adhesion', 'pathways in cancer', 'ECM-receptor interaction', 'regulation of actin cytoskeleton' and 'small cell lung cancer' (Table III) .
PLK1 was significantly upregulated in LB2BC (Table I) . PLK1 is a key regulator of cell division and is overexpressed in numerous types of human cancer, including prostate, pancreatic and breast cancer (28) . PLK1 is significantly enriched in the 'cell cycle' and 'progesterone-mediated oocyte maturation' pathways (Table III) . PLK1 was identified as downregulated in LB2BC as assessed by RT-qPCR, whereas the opposite result was obtained in DEG analysis (Fig. 3C) ; this may be due to the small experimental sample size (n=5) used in the present study. PLK1 was a hub protein, interacting with 153 genes in the PPI network (Fig. 2 ). PLK1 encodes a serine/threonine protein kinase that belongs to the cell cycle serine/threonine-protein kinase CDC5/Polo subfamily. PLK1 is significantly overexpressed in triple-negative breast cancer (TNBC), compared with other breast cancer subtypes; the inhibition of PLK1 activity induces an increase in G2/M cell cycle arrest and TNBC cell apoptosis (29) . PLK1 is overexpressed in breast cancer cell lines compared with normal breast cell lines; silencing PLK1 enhances the sensitivity of breast cancer cell lines to rapamycin (30) .
EGFR expression was significantly downregulated in LB2BC, as observed via DEG analysis and validated using RT-qPCR (Table I ; Fig. 3D ). EGFR was the hub protein with the highest connectivity degree, connecting to 781 genes in the PPI network. EGFR was significantly enriched in several pathways, including pathways in cancer and the MAPK signaling pathway (Table III) . EGFR was previously identified as upregulated in various types of cancer, including lung cancer, gastric cancer and glioblastoma (31) (32) (33) . EGFR is frequently overexpressed in TNBC; high EGFR gene copy number predicts a poor patient outcome (34) . EGFR expression was downregulated in LB2BC in the present study, indicating that the pathogenesis of LB2BC is distinct from TNBC.
In conclusion, 2,251 DEGs were identified between LB2BC and non-tumor tissue. The top 15 upregulated and downregulated genes in LB2BC were used to construct a PPI network. A number of genes, including NTRK2, FN1, PLK1 and EGFR, were identified that potentially serve critical roles in the pathogenesis of LB2BC via the 'focal adhesion', 'pathways in cancer' and 'ECM-receptor interaction signaling' KEGG pathways. The findings of the present study may contribute to the further elucidation of the pathogenesis of LB2BC.
